Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Northwest Biotherapeutics, Inc. (NWBO) had Return on Tangible Equity of 3.38% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.49M |
|
$-3.40M |
|
-- |
|
$0.49M |
|
$11.39M |
|
$-10.90M |
|
$7.83M |
|
$-3.07M |
|
$-3.07M |
|
$-3.07M |
|
$-3.07M |
|
$-3.07M |
|
$-3.07M |
|
$-10.90M |
|
$-9.85M |
|
1.58B |
|
1.58B |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$6.20M |
|
$16.77M |
|
$73.85M |
|
$80.05M |
|
$82.97M |
|
$1.49M |
|
$35.14M |
|
$118.11M |
|
$-50.54M |
|
$-90.73M |
|
$-38.06M |
|
1.61B |
|
| Cash Flow Statement Financials | |
$-12.51M |
|
$-0.13M |
|
$9.21M |
|
$3.04M |
|
$1.79M |
|
$-1.25M |
|
$0.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.07 |
|
-- |
|
-- |
|
-0.04 |
|
-1.17 |
|
100.00% |
|
-2206.48% |
|
-2206.48% |
|
-- |
|
-621.26% |
|
-688.26% |
|
$-12.64M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
6.07% |
|
|
Return on Tangible Equity |
3.38% |
-3.83% |
|
8.39% |
|
$-0.02 |
|
$-0.01 |
|
$-0.01 |
|